A Phase 1 interventional study of Clarithromycin and Amoxicillin in Helicobacter Pylori, sponsored by Takeda. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-01-03.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.
This is a phase 1, double-blind, parallel group study in participants with Helicobacter pylori (HP positive) who are, additionally, cytochrome P-450 (CYP)2C19 extensive metabolizers (EM) to evaluate the safety, tolerability and pharmacokinetics (PK) of a quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole. The study will enroll 30 participants.
The treatment phase consists of quadruple therapy twice daily (BID) with tripotassium bismuth dicitrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg), and TAK-438 (20 mg) (Group B) or quadruple therapy BID with tripotassium bismuth dicitrate (600 mg), clarithromycin (500 mg), amoxicillin (1000 mg),and lansoprazole (30 mg) (Group A) from Days 1 to 14. Participants will be discharged on Day 15 after final PK blood samples are collected and all procedures performed.
This single-center will be conducted in Korea. Participants will remain confined to the study site from check-in (Day -1) through Day 15 and will followed up through call on Day 17 and return on Day 42 for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
Drug: Clarithromycin · Drug: Amoxicillin · Drug: Tripotassium bismuth dicitrate · Drug: Lansoprazole
Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
Drug: Clarithromycin · Drug: Amoxicillin · Drug: Tripotassium bismuth dicitrate · Drug: TAK-438
Clarithromycin tablets
Amoxicillin capsules
Tripotassium bismuth dicitrate tablets
Lansoprazole capsules
TAK-438 tablets
Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
Time frame: Baseline up to Day 17
Percentage of Participants Who Discontinue Due to an Adverse Event (AE)
Time frame: Baseline up to Day 17
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post-dose
Time frame: Baseline up Day 15
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose
Time frame: Baseline up to Day 15
Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose
Time frame: Baseline up to Day 15
Cmax: Maximum Observed Plasma Concentration for Bismuth
Time frame: Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth
Time frame: Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth
Time frame: Day 14 pre-dose and at multiple timepoints (up to 12 hours) post-dose
Participants took part in the study at 1 investigative site in Korea from 05 September 2016 to 11 May 2017.
| Milestone | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Started | 15 | 15 |
| Completed | 12 | 14 |
| Not completed | 3 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| percentage of participants | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) | 53.3 | 66.7 |
| percentage of participants | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Percentage of Participants Who Discontinue Due to an Adverse Event (AE) | 6.7 | 0.0 |
| percentage of participants | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Amylase (greater than [>] 2*upper limit of normal) | 0.0 | 6.7 |
| Potassium (>6.0 millimole per liter [mmol/L]) | 0.0 | 6.7 |
| percentage of participants | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Body temperature (less than [<] 35.6 celsius [C]) | 0.0 | 6.7 |
| Body temperature (>37.7 C) | 6.7 | 6.7 |
| Systolic blood pressure(<85 millimeter of mercury) | 6.7 | 6.7 |
| Diastolic blood pressure(<50millimeter of mercury) | 6.7 | 6.7 |
| percentage of participants | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post-dose | 0.0 | 6.7 |
| nanogram per milliliter (ng/mL) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Bismuth | 28.08 ± 11.691 | 30.14 ± 24.612 |
| hours nanogram per milliliter (h*ng/mL) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Bismuth | 103.0 ± 37.498 | 111.1 ± 45.010 |
| nanogram (ng) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for Bismuth | 497300 ± 202270 | 537600 ± 188340 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and up to Day 17. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Clarithromycin + Amoxicillin + Bismuth + TAK-438 | 0/15 (0%) | 0/15 (0%) | 8/15 (53.3%) |
| Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| Event | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole |
|---|---|---|
| DysgeusiaNervous system disorders | 0/15 | 3/15 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/15 | 3/15 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 3/15 | 1/15 |
| Faeces discolouredGastrointestinal disorders | 1/15 | 2/15 |
| Feeling hotGeneral disorders | 2/15 | 1/15 |
| PalpitationsCardiac disorders | 1/15 | 0/15 |
| HyperthyroidismEndocrine disorders | 1/15 | 0/15 |
| Eye pruritusEye disorders | 0/15 | 1/15 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 1/15 |
| DyspepsiaGastrointestinal disorders | 1/15 | 0/15 |
The safety analysis set included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| Mean | 32.8 ± 6.87 | 33.3 ± 8.61 | 33.1 ± 7.66 |
| Sex: Female, Male(Participants) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 14 | 14 | 28 |
| Race (NIH/OMB)(Participants) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 15 | 15 | 30 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Height(centimeter (cm)) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| Mean | 173.7 ± 5.04 | 168.9 ± 5.14 | 171.3 ± 5.56 |
| Weight(kilogram (kg)) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| Mean | 72.41 ± 5.028 | 66.05 ± 8.395 | 69.23 ± 7.528 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| Mean | 24.03 ± 1.795 | 23.13 ± 2.271 | 23.58 ± 2.064 |
| Smoking Classification(Participants) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| Never smoked | 14 | 12 | 26 |
| Ex-smoker | 1 | 3 | 4 |
| Alcohol Consumption(Participants) | Clarithromycin + Amoxicillin + Bismuth + TAK-438 | Clarithromycin + Amoxicillin + Bismuth + Lansoprazole | Total |
|---|---|---|---|
| Drank a couple of days per week | 2 | 0 | 2 |
| Drank a couple of days per month | 4 | 6 | 10 |
| Never Drank | 9 | 9 | 18 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Apr 2017, 7 months.
Results were first posted in Jan 2019, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amoxicillin · Vonoprazan